Histidine Supplementation for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for Alzheimer's disease.Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months. Baseline evaluation and followup evaluation at 3 months postop.
Research Team
Wells Reynolds, MD
Principal Investigator
Wake Forest University Health Sciences
Eligibility Criteria
This trial is for individuals with Alzheimer's Disease who are interested in testing whether a dietary supplement, l-Histidine, can improve their cognitive function. Participants will be randomly assigned to receive either the Histidine supplement or a placebo for three months.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either Histidine or placebo for up to 3 months, with titrated dosing of L-histidine in the treatment arm
Follow-up
Participants are monitored for safety and effectiveness after treatment, with cognitive testing and lab evaluations
Treatment Details
Interventions
- Histidine Oral Supplementation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor